hydroxychloroquine has been researched along with Urticaria in 18 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the chronic autoimmune urticaria study and evaluation was to evaluate the efficacy of hydroxychloroquine in patients with chronic idiopathic urticaria." | 9.11 | Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. ( Bonfield, J; Boyle, MJ; Dobson, P; Loewenthal, M; Reeves, GE, 2004) |
| "The aim of the chronic autoimmune urticaria study and evaluation was to evaluate the efficacy of hydroxychloroquine in patients with chronic idiopathic urticaria." | 5.11 | Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. ( Bonfield, J; Boyle, MJ; Dobson, P; Loewenthal, M; Reeves, GE, 2004) |
| "Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection." | 1.56 | [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]. ( Bouchti, IE; Malek, SA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 9 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, N | 2 |
| Epstein, TG | 2 |
| DuBuske, I | 1 |
| Strobel, M | 1 |
| Bernstein, DI | 2 |
| Kaplan, AP | 1 |
| Rowane, M | 1 |
| Schend, J | 1 |
| Patel, J | 1 |
| Hostoffer, R | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Nasiri, S | 1 |
| Dadkhahfar, S | 1 |
| Abasifar, H | 1 |
| Mortazavi, N | 1 |
| Gheisari, M | 1 |
| Bostan, E | 1 |
| Akdogan, N | 1 |
| Gokoz, O | 1 |
| Dogan, S | 1 |
| Malek, SA | 1 |
| Bouchti, IE | 1 |
| Veraldi, S | 1 |
| Romagnuolo, M | 1 |
| Benzecry, V | 1 |
| Jachiet, M | 2 |
| Flageul, B | 2 |
| Bouaziz, JD | 1 |
| Bagot, M | 2 |
| Terrier, B | 2 |
| Boonpiyathad, T | 1 |
| Sangasapaviliya, A | 1 |
| Iweala, OI | 1 |
| Copenhaver, C | 1 |
| Wu, EY | 1 |
| Moran, TP | 1 |
| Deroux, A | 1 |
| Le Quellec, A | 1 |
| Maurier, F | 1 |
| Cordoliani, F | 1 |
| Godmer, P | 1 |
| Abasq, C | 1 |
| Astudillo, L | 1 |
| Belenotti, P | 1 |
| Bessis, D | 1 |
| Bigot, A | 1 |
| Doutre, MS | 1 |
| Ebbo, M | 1 |
| Guichard, I | 1 |
| Hachulla, E | 1 |
| Héron, E | 1 |
| Jeudy, G | 1 |
| Jourde-Chiche, N | 1 |
| Jullien, D | 1 |
| Lavigne, C | 1 |
| Machet, L | 1 |
| Macher, MA | 1 |
| Martel, C | 1 |
| Melboucy-Belkhir, S | 1 |
| Morice, C | 1 |
| Petit, A | 1 |
| Simorre, B | 1 |
| Zenone, T | 1 |
| Bouillet, L | 1 |
| Frémeaux-Bacchi, V | 1 |
| Guillevin, L | 1 |
| Mouthon, L | 1 |
| Dupin, N | 1 |
| Aractingi, S | 1 |
| Calistru, AM | 1 |
| Lisboa, C | 1 |
| Cruz, MJ | 1 |
| Delgado, L | 1 |
| Poças, L | 1 |
| Azevedo, F | 1 |
| RUBENSTEIN, M | 1 |
| WOLFF, SM | 1 |
| Reeves, GE | 1 |
| Boyle, MJ | 1 |
| Bonfield, J | 1 |
| Dobson, P | 1 |
| Loewenthal, M | 1 |
| Batioğlu, F | 1 |
| Taner, P | 1 |
| Aydintuğ, OT | 1 |
| Heper, AO | 1 |
| Ozmert, E | 1 |
| Lopez, LR | 1 |
| Davis, KC | 1 |
| Kohler, PF | 1 |
| Schocket, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Efficacy in Chronic Urticaria[NCT01073852] | 0 participants (Actual) | Interventional | 2011-06-30 | Withdrawn (stopped due to withdrawn, not funded) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for hydroxychloroquine and Urticaria
| Article | Year |
|---|---|
Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study.
Topics: Adult; Anti-Allergic Agents; Chronic Disease; Drug Resistance; Female; Histamine Antagonists; Humans | 2017 |
Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation.
Topics: Adult; Autoimmune Diseases; Chronic Disease; Dermatologic Agents; Female; Humans; Hydroxychloroquine | 2004 |
16 other studies available for hydroxychloroquine and Urticaria
| Article | Year |
|---|---|
Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study.
Topics: Anti-Allergic Agents; Chronic Disease; Chronic Urticaria; Humans; Hydroxychloroquine; Omalizumab; Re | 2022 |
Reply to "Does hydroxychloroquine work for chronic spontaneous urticaria?"
Topics: Chronic Urticaria; Humans; Hydroxychloroquine; Urticaria | 2023 |
Does hydroxychloroquine work for chronic spontaneous urticaria?
Topics: Chronic Disease; Chronic Urticaria; Humans; Hydroxychloroquine; Urticaria | 2023 |
Rapid desensitization of hydroxychloroquine.
Topics: Anti-Inflammatory Agents; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hydro | 2020 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
Urticarial vasculitis in a COVID-19 recovered patient.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Histamine Antago | 2020 |
Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis.
Topics: Humans; Hydroxychloroquine; Prednisolone; Urticaria; Vasculitis | 2020 |
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Urticaria as a first clinical manifestation of COVID-19.
Topics: Acetaminophen; Adult; Antiviral Agents; Cetirizine; COVID-19; COVID-19 Drug Treatment; Dermatologic | 2020 |
[Hypocomplementemic urticarial vasculitis].
Topics: Colchicine; Complement C1q; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive A | 2018 |
Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria.
Topics: Acetates; Anti-Inflammatory Agents; Antimalarials; Cetirizine; Chronic Disease; Cyclopropanes; Diphe | 2018 |
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colchicine; Comorbidity; Complement C1q; Female; France; | 2015 |
Hypocomplementemic urticarial vasculitis in mixed connective tissue disease.
Topics: Complement C3c; Complement C4; Female; Humans; Hydroxychloroquine; Middle Aged; Mixed Connective Tis | 2010 |
PENILE NODULES AS A MAJOR MANIFESTATION OF SUBACUTE ANGIITIS.
Topics: Humans; Hydroxychloroquine; Infectious Mononucleosis; Male; Neuritis; Pathology; Penis; Prednisone; | 1964 |
Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis.
Topics: Anti-Infective Agents; Dermatologic Agents; Drug Industry; Drug Therapy, Combination; Female; Glucoc | 2006 |
The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine.
Topics: Adult; Biopsy; Complement Activating Enzymes; Complement C1q; Hemolytic Plaque Technique; Humans; Hy | 1984 |